Cellular ATP serves as an energy carrier that drives virtually all cell functions. Therefore, the discovery that intact cells can release a portion of their cellular ATP came as a surprise to most researchers 1 . Over the last 2 decades, a total of 19 different purinergic receptor subtypes that can recognize extracellular ATP and adenosine have been cloned and characterized 2 . These receptors include eight P2Y receptor subtypes, seven P2X receptor subtypes, and four P1 (adenosine) receptor subtypes. In addition, several families of ectonucleotidases that hydrolyse ATP to ADP, AMP and adenosine have been found 3 . Distinct sets of these purinergic receptors and ectonucleotidases are expressed on the cell surface of different mammalian cell types, where they regulate cell activation through cell-type specific purinergic signalling systems 4,5 . Controlled ATP release from intact cells was first discovered in neurons, which release ATP into neuronal synapses. Since then, many aspects of purinergic signalling in neurons have been elucidated 6 . Additional work revealed that similar purinergic signalling mechanisms regulate key aspects of many other physiological processes, including activation of the different cell types of the immune system 7 . For example, T cell activation induces the release of ATP through pannexin 1 channels that translocate with P2X receptors to the immune synapse, where they promote calcium influx and cell activation through autocrine purinergic signalling [8] [9] [10] [11] . Neutrophils release ATP in response to chemotactic mediators, and autocrine signalling through purinergic receptors regulates the chemotaxis of these cells 12 . Activation of purinergic receptors in immune cells can elicit either positive or negative feedback mechanisms and thus can tightly regulate immune responses.
In addition to the autocrine feedback mechanisms that regulate the function of healthy immune cells, purinergic receptors allow immune cells to recognize the ATP that is released from damaged or stressed host cells. Thus, the purinergic signalling systems of immune cells serve an important function in the recognition of 'danger' signals, and ATP that is released by stressed cells acts as a 'find-me signal' that guides phagocytes to inflammatory sites and promotes clearance of damaged and apoptotic cells 13 . Purinergic signalling is also crucial for the activation of inflammasomes and the subsequent release of cytokines, such as interleukin-1β (IL-1β), in response to damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) 14 . Several excellent review articles have been published that describe in detail the mechanisms by which mammalian cells release ATP 15 , the pharmacological and structural properties of the different purinergic receptors [16] [17] and ectonucleotidases 18 , and the multiple roles for paracrine purinergic signalling in regulating a wide range of physiological processes, including immune cell functions 5, 7 . This Review will therefore mainly focus on the roles of autocrine purinergic signalling systems in immune cell activation (FIG. 1) and how these purinergic systems integrate extracellular cues, such as danger signals from inflamed tissues.
Immune synapse
A large junctional structure that is formed at the cell surface between a T cell and an antigen-presenting cell. It is also known as the supramolecular activation cluster. Important molecules that are involved in T cell activation -including the T cell receptor, numerous signal-transduction molecules and molecular adaptorsaccumulate in an orderly manner at this site. Immune synapses are now known to also form between other types of immune cells; for example, between dendritic cells and natural killer cells.
Immune cell regulation by autocrine purinergic signalling
Wolfgang G. Junger* ‡ Abstract | Stimulation of almost all mammalian cell types leads to the release of cellular ATP and autocrine feedback through a diverse array of purinergic receptors. Depending on the types of purinergic receptors that are involved, autocrine signalling can promote or inhibit cell activation and fine-tune functional responses. Recent work has shown that autocrine signalling is an important checkpoint in immune cell activation and allows immune cells to adjust their functional responses based on the extracellular cues provided by their environment. This Review focuses on the roles of autocrine purinergic signalling in the regulation of both innate and adaptive immune responses and discusses the potential of targeting purinergic receptors for treating immune-mediated disease.
Find-me signal
A signal emitted by dying cells to promote the recruitment of scavenger cells, which clear the apoptotic cell body.
Inside-out signalling
The process by which intracellular signalling mechanisms result in the activation of cell surface receptors, such as integrins. By contrast, outside-in signalling is the process by which ligation of a cell surface receptor activates signalling pathways inside the cell.
Components of purinergic signalling ATP release. Immune cells recognize ATP that is released from damaged tissues and dying cells as a danger signal that elicits a variety of inflammatory responses [19] [20] [21] . In addition to damaged cells, intact cells (including immune cells themselves) can release ATP under normal physiological conditions. ATP release from intact cells was first observed in neuronal cells, which use vesicular transport to release ATP into the cleft of chemical synapses 22 . Non-neuronal cell types can also release ATP through vesicular transport 5 ; however a number of additional mechanisms have been reported. These mechanisms include release through stretch-activated channels, voltage-dependent anion channels, P2X7 receptors (a purinergic receptor subtype involved in opening large pores in the cell membrane), and connexin and pannexin hemichannels 15 . Pannexin 1 hemichannels were recently found to promote ATP release from several immune cell types. Similarly to connexin hemichannels, pannexin hemichannels are thought to form gap junctions between adjacent cells and enable rapid intercellular communication. In individual cells, including immune cells, these hemichannels can release ATP. The pannexin family has three members (pannexin 1-3) and these proteins are distant relatives of the larger connexin family, which has 21 members [23] [24] [25] . In mouse neutrophils, ATP release appears to occur through connexin 43 hemichannels 26 . human neutrophils release ATP through pannexin 1 channels in response to stimulation of formyl-peptide receptors (FPRs), Fcγ receptors, IL-8 receptors, complement C5a receptors and leukotriene B 4 receptors 27 . Pannexin 1 also facilitates ATP release from T cells after activation of the T cell receptor (TCR) and the CD28 costimulatory receptor, or following exposure of T cells to osmotic stress 9, 11 . The surface expression of pannexin 1 is highly dynamic, and activation of a T cell or neutrophil causes translocation and accumulation of pannexin 1 at the T cell immune synapse or the leading edge of the polarized neutrophil, respectively 11, 27 . Extracellular ATP metabolism. Following its release into the extracellular space, ATP is rapidly hydrolysed in a stepwise manner to ADP, AMP and adenosine by ectonucleotidases 18 . This process terminates P2 receptor activation, prevents receptor desensitization and sets the stage for rapid and repeated signalling through purinergic inside-out signalling via purinergic receptors. Four families of ectonucleotidases that hydrolyse extracellular ATP have A schematic of the key elements involved in purinergic signalling. Receptor activation (for example, stimulation of formyl-peptide receptors (FPRs) by N-formylmethionyl-leucyl-phenylalanine (fMLP)) leads to the opening of pannexin 1 hemichannels and the release of ATP from the cell. Released ATP promotes the autocrine activation of P2 receptors. Ectonucleotidases (such as ectonucleoside triphosphate diphosphohydrolases (ENTPDs) and ecto-5'-nucleotidase (also known as CD73)) promote hydrolysis of ATP and the formation of adenosine, which activates P1 receptors. Adenosine is 'neutralized' by adenosine deaminase, which converts adenosine to inosine, or recycled through concentrative nucleoside transporters (CNTs) or equilibrative nucleoside transporters (ENTs). Autocrine purinergic signalling provides cells with quantitative cues that define how and to what extent the cells respond to the qualitative cues that they perceive through specific surface receptors that detect pathogens, antigens, chemokines and cytokines. Autocrine purinergic mechanisms allow localized stimulation because signalling molecules can be confined to specific regions, and different spatio-temporal combinations of signalling components can be arranged to meet specific functional requirements. Moreover, these autocrine feedback processes can be influenced in a paracrine fashion by purinergic receptor ligands that are generated by other cells, for example, in infected or damaged tissues.
been identified in mammalian cells. These ectoenzymes include the ectonucleoside triphosphate diphosphohydrolase (eNTPD) family, the ectonucleotide pyrophosphatase/phosphodiesterase (eNPP) family, the alkaline phosphatase family and ecto-5ʹ-nucleotidase (also known as CD73) 3, 18, 28 . The eNTPD family comprises seven different isoforms (eNTPD1-6 and eNTPD8), of which eNTPD1-3 and eNTPD8 are known to hydrolyse ATP or ADP to AMP with different substrate preferences. The three members of the eNPP family (eNPP1-3) hydrolyse ATP to AMP and pyrophosphate. Finally, the four members of the alkaline phosphatase family (intestinal, placental, germ cell and tissue-nonspecific alkaline phosphatase) can hydrolyse ATP, ADP and AMP to adenosine, and the sole ecto-5ʹ-nucleotidase isoform converts AMP to adenosine 3, 18 . ectonucleotidases are found on the surfaces of virtually all mammalian cell types with distinct distribution patterns that define cell-specific local purinergic ligand environments.
Adenosine turnover and cellular reuptake. extracellular adenosine, the ligand of P1 receptors, can be removed either by adenosine deaminase, which converts adenosine to inosine, or by cellular reuptake through concentrative nucleoside transporters (CNTs) or equilibrative nucleoside transporters (eNTs) 29, 30 . In addition to these mechanisms, adenosine kinase can convert extracellular adenosine back to AMP
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. Two different adenosine deaminase isoforms, ADA and CeCR1 (also known as ADA2), are found on the surface of many cell types, including leukocytes [31] [32] [33] [34] [35] . Both isoforms promote co-stimulatory signalling at the immune synapse, resulting in increased production of T helper 1 (T h 1)-type cytokines and increased T cell proliferation 36, 37 . The importance of ADA is further underscored by the fact that a genetic disorder resulting in ADA deficiency causes severe combined immunodeficiency (SCID) -a condition characterized by impaired T and B cell development and an increased risk of infection -owing to excessive A2A adenosine receptor activation 36, 38, 39 . Adenosine reuptake is accomplished by two structurally unrelated families of nucleoside transporters: the four equilibrative nucleoside transporters (eNT1-4; also known as SLC29A1-4) and the three concentrative nucleoside transporters (CNT1-3; also known as SLC28A1-3) 29, 30, 39 . The best characterized eNT family members, eNT1 and eNT2, are inhibited by widely used drugs such as dipyridamole, dilazep and draflazine 40 . eNTs are involved in the activation of T cells 41 , B cells 42 and macrophages 43 . Although nucleoside transporters have been linked with lymphocyte proliferation 44 , little is known about the underlying mechanisms. however, the ubiquitous expression of nucleoside transporters in different tissues suggests that they may 'recharge' purinergic signalling systems by recycling adenosine.
Purinergic receptors.
The most widely studied elements of purinergic signalling systems are the purinergic receptors that respond to extracellular ATP, adenosine and related nucleotides. Purinergic receptors are divided into three major families based on their pharmacological and structural properties 2 (TABLE 1) . P2X receptors function as ATP-gated ion channels that facilitate the influx of extracellular cations, including calcium ions. Although all the P2X receptors respond only to ATP, they do so with different ligand affinities and ligand-induced receptor desensitization kinetics 45 . Among P2X receptors, the P2X7 subtype has a special role, as micromolar ATP concentrations elicit its ion channel function, whereas higher ATP concentrations (in the millimolar range) induce P2X7 to form large conductance pores that are involved in apoptosis 45 . P2Y receptors are G protein-coupled receptors (GPCRs) that recognize ATP and several other nucleotides, including ADP, uTP, uDP and uDP-glucose. These receptors can bind to a number of different G proteins (TABLE 1) . P1 receptors are also GPCRs and recognize adenosine. A2A and A2B receptors couple to stimulatory G proteins (G s ) and typically suppress cell responses by upregulating intracellular cyclic AMP levels. By contrast, A1 and A3 receptors couple to G i/o or G q/11 proteins and promote cell activation.
Purinergic signalling systems. Different cell types express distinct sets of the purinergic signalling components described above, and this allows the formation of customized purinergic signalling complexes (FIG. 1) . These complexes permit immune cells to mount unique responses to ATP, adenosine and the other ligands described in TABLE 1. The role of purinergic signalling as a paracrine mechanism of intercellular communication among immune cells has been widely recognized 7 . however, recent findings show that purinergic signalling in immune cells has additional roles that are less well known. ATP released from damaged or stressed cells serves as an important danger signal that induces specific immune responses, and ATP can be released from immune cells themselves in response to normal cell stimulation. This triggers autocrine purinergic feedback mechanisms that are essential regulators of immune cell responses. Crosstalk between paracrine signals and autocrine purinergic signalling mechanisms makes it possible for immune cells to adapt their responses to the extracellular cues generated by the surrounding cells in different tissues.
Purinergic signalling and immune responses
Immune cells have developed highly sensitive receptor systems that allow them to execute their many roles in immune surveillance and host defence. To perform these tasks effectively, neutrophils, for example, must detect trace amounts of the chemoattractants that help them locate and migrate to sites of infection and inflammation 46 . T cells are able to perform the astonishingly difficult task of recognizing individual peptide-MhC complexes with great selectivity and sensitivity 47 . Although it is clear that these extraordinary feats require sophisticated signalamplification systems, the nature of these amplification mechanisms has remained unclear. Recent findings have shown that stimulation of neutrophils and T cells leads to the rapid release of ATP, which triggers autocrine purinergic feedback loops that amplify the weak stimuli these cells receive during cell activation.
Regulation of neutrophil and macrophage chemotaxis.
Stimulation of chemotaxis receptors induces rapid ATP release from neutrophils, and this is necessary to promote neutrophil recognition of chemotactic gradients and guide these cells to infected or inflamed tissues 12 . A new method that allows direct imaging of ATP release from live cells has revealed that ATP is released in a polarized manner, resulting in the accumulation of extracellular ATP near the cell surface closest to the source of chemoattractants. The released ATP can activate multiple adjacent P2Y2 receptors to provide autocrine signal amplification, which greatly increases the intracellular signals generated by chemotactic stimuli (FIG. 2) . Inhibiting purinergic signalling by blocking ATP release or P2Y2 receptors, or by expediting the removal of extracellular ATP, impairs chemotaxis. Similarly, overwhelming the endogenous autocrine purinergic systems by adding excessive exogenous ATP also blocks chemotaxis 12 . Thus, altering ATP concentrations in the extracellular environment can modulate chemotaxis by interfering with the autocrine signalling systems of neutrophils.
Chemotaxis is a complex process that involves gradient sensing, cell polarization and directed migration. Gradient sensing is the process by which a cell detects chemoattractants and recognizes differences in chemoattractant concentrations in its extracellular environment. During cell polarization, a cell assumes an elongated shape that aligns within the chemotactic gradient field. At the same time, specific receptors and signalling molecules translocate to the leading and trailing edges of the cell. Finally, directed migration is the actual forward . cAMP, cyclic AMP; EC 50 , half-maximum effective concentration; InsP 3 , inositol-1,4,5-trisphosphate; ND, not detected; NK, natural killer; PLCβ, phospholipase Cβ. *In addition to the P2Y receptors shown in this table, genes encoding the related receptors P2Y3, P2Y5, P2Y7, P2Y8, P2Y9, P2Y10 were cloned but found not to respond to purinergic ligands, except for P2Y3, which is an avian analogue of the mammalian P2Y6 receptor. movement of a cell within a chemoattractant gradient field. Recent studies have shown that autocrine purinergic feedback mechanisms control several aspects of these different processes. Initially, stimulation of a chemotaxis receptor induces ATP release and the activation of multiple adjacent P2Y2 receptors. This process can be thought of as an inside-out signalling event, in which ATP serves as a second messenger that amplifies chemotaxis signals through nearby P2Y2 receptors. During cell polarization, purinergic signalling molecules (such as pannexin 1, eNTPD1 and A3 adenosine receptors) translocate to the leading edge of the cell, where membrane ruffling and pseudopod protrusion lead to the release of additional ATP, which is converted to adenosine by eNTPD1 (REFS 12, 27, 48) . Finally, adenosine activates A3 receptors that are concentrated at the leading edge, and this additional purinergic feedback loop promotes migration and forward movement of neutrophils towards the source of chemoattractants 49 (FIG. 2) .
exogenous ATP and adenosine have long been known to modulate neutrophil responses [50] [51] [52] [53] [54] [55] [56] . The discovery of the autocrine purinergic signalling systems described above sheds light on the underlying mechanisms by which these compounds regulate chemotaxis. Similar autocrine signalling systems were recently identified in macrophages and these regulate chemotaxis through P2Y2 and A3 receptors, as well as through P2Y12, A2A and A2B receptors 57 . Interestingly, A2A receptors also have a role in the chemotaxis of microglial cells, controlling uropod retraction in these cells 58 . In addition to the GPCR type of purinergic receptors that are involved in these responses 12, 57, 59 , recent work by Lecut et al. 60 has shown that the structurally distinct P2X1 receptor can regulate the chemotaxis of neutrophils through the activation of RhO family kinases.
Regulation of chemotaxis in other immune cells.
Purinergic signalling may also be involved in the chemotaxis of other immune cell types. ATP itself, when released from injured cells, has been reported to promote chemotactic and phagocytic responses in microglia through P2Y12 and P2Y13 receptors, and P2Y6 receptors, respectively [61] [62] [63] [64] [65] [66] . Similar observations were reported for mast cells, monocytes, dendritic cells and eosinophils [67] [68] [69] [70] . however, a drawback of many of these studies is that chemotaxis was not observed directly (that is, under a microscope), but was instead monitored indirectly using transwell assay systems, which do not differentiate between chemotaxis and chemokinesis. Thus, it is possible that ATP increases random migration of some of these cell types rather than promoting chemotaxis. Similarly, purinergic receptor knockout or silencing experiments, although extremely useful, can yield ambiguous results that must be considered carefully because loss of chemotaxis does not necessarily indicate that a specific purinergic receptor is a true chemotaxis receptor. Instead, the receptor may be required for autocrine purinergic signalling that regulates chemotaxis in This induces the release of ATP through pannexin 1 hemichannels and thus results in the activation of P2Y2 receptors, which provide signal amplification and facilitate the sensing of chemotactic gradients (left). These signalling mechanisms allow the cell to polarize within the chemotactic gradient field (centre) and induce the translocation of pannexin 1, ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1, also known as CD39) and A3 receptors to the leading edge of the cell. Accumulation of these purinergic signalling components focuses ATP release and the formation of adenosine at the leading edge and results in autocrine activation of A3 receptors, which promote cell migration towards the source of fMLP (right). Preliminary evidence suggests that negative autocrine feedback through A2A adenosine receptors (which block cell activation and remain uniformly distributed across the cell surface) supports chemotaxis by promoting the retraction of the trailing edge of the cell (W.G.J., unpublished observations) (not depicted in the figure). [71] [72] [73] [74] . Such interconnected mechanisms, including ATP release, inflammasome activation, IL-8 secretion and FPR-mediated chemotaxis, were recently shown to regulate recruitment of neutrophils to sites of inflammation 75 . however, the authors concluded that ATP released from inflammatory sites does not serve as a chemoattractant. This is in contrast to other reports suggesting that apoptotic cells release ATP through pannexin 1 and that ATP itself acts as a powerful 'find-me' signal that recruits monocytes 13, 76 . It remains to be seen whether this response involves additional chemotactic mediators that are released from apoptotic cells along with ATP. Given the ubiquitous nature of ATP release by healthy cells, chemotaxis towards ATP would seem counterproductive under most physiological circumstances. Thus, it seems more likely that released ATP regulates chemotaxis rather than inducing it (FIG. 3) .
Signal amplification in T cells. T cells recognize antigens through their TCRs, which localize to the immune synapse and physically interact with peptides that are presented on MhC molecules by antigen-presenting cells (APCs). A surprisingly low number of peptide-MhC complexes are required for T cell activation 77 , and it is unclear how such weak signals are able to provide sufficiently strong stimulatory signals to activate T cells during their brief encounter with APCs. In order to respond with high sensitivity and selectivity to their antigens, it is clear that T cells must possess mechanisms that permit signal amplification 78 . Several models of TCR signalling have been proposed 47, 78 . The serial-triggering model assumes that a single peptide-MhC complex can activate multiple TCRs in fast succession. Kinetic proofreading models may explain how T cells can either be activated or remain in a resting state based on very small differences in the antigen-binding affinities of their TCR for the different antigens they encounter. Cooperative models propose that multiple TCR complexes cooperate through physical contact or second messengers, allowing T cells to distinguish rare high-affinity antigens from the high background signal generated by the abundance of low-affinity antigens. It has also been proposed that mechanical forces exerted on T cells and accessory cells as a result of TCR engagement are crucial for T cell activation and antigen recognition 79 . Recent evidence suggests that purinergic signalling at the immune synapse could serve as a signal amplification mechanism needed for antigen recognition. A number of studies have shown that T cells can release ATP in response to various extracellular stimuli, suggesting that purinergic signalling may indeed play an active role in T cell activation 8, 80, 81 . T cells express many members of the P2X, P2Y and P1 receptor families, as well as the eNTPD1 ectonucleotidase [82] [83] [84] . Recent findings by Schenk et al. 9 have revealed that TCR stimulation triggers the release of cellular ATP through pannexin 1 channels. Pannexin 1 translocates to the immune synapse, where it releases ATP and promotes T cell activation, suggesting that autocrine purinergic feedback processes, similar to those identified in neutrophils, also regulate T cell activation 9-11 . however, although neutrophils seem to amplify stimulatory signals using P2Y2 receptors, purinergic signal amplification in T cells occurs through P2X1, P2X4 and P2X7 receptors. Phagocytes, such as neutrophils, monocytes and macrophages, require autocrine purinergic signalling to detect and migrate in response to chemoattractants and danger signals issuing from inflamed and infected sites. Long-range chemotactic signals, such as N-formyl-methionyl-leucyl-phenylalanine (fMLP) and interleukin-8 (IL-8) promote the recruitment of phagocytes to inflamed tissues. ATP that is released from dying cells at the site of inflammation is short lived and can, therefore, only serve as a short-range signal to neighbouring phagocytes. The ATP released from the dying cells promotes their uptake by phagocytes by interfering with autocrine purinergic signalling mechanisms (and thus trapping phagocytes within the vicinity) and by upregulating phagocytosis and other phagocyte killing mechanisms, resulting in clearance of the dying cells.
P2X receptors function as calcium channels, and autocrine activation of these receptors facilitates calcium influx and downstream signalling, leading to IL2 transcription 11 . Interestingly, two of the three P2X receptor subtypes that are involved in this autocrine signalling process, P2X1 and P2X4, translocate along with pannexin 1 to the immune synapse within minutes of TCR stimulation 11 . This increases the effectiveness of purinergic signalling by concentrating key signalling elements within the immune synapse. Although P2X7 receptors are found at the immune synapse, they do not translocate in response to TCR stimulation and the majority of P2X7 receptors remain uniformly distributed across the cell surface. This suggests that different P2X receptor subtypes have different functions during the various stages of T cell activation, and that P2X7 receptors may allow T cells to remain responsive to ATP generated by surrounding tissues and cells that are not directly involved in antigen presentation.
Similarly to the relocalization of signalling molecules to the leading edge of polarized neutrophils, the translocation of pannexin 1 and P2X receptors to the T cell immune synapse promotes strong positive purinergic feedback mechanisms, which are further amplified in the confined space of the synaptic cleft (FIG. 4) . under such conditions, it is feasible that ATP released in response to the engagement of a single TCR complex could indeed result in the activation of a sufficiently large number of P2X receptors to elicit powerful and selective T cell responses.
Regulation of other immune cells.
Although there is no direct proof, ample indirect evidence suggests that autocrine purinergic signalling could also regulate the activation of many other immune cell types in addition to those discussed above. Most immune cells express at least some of the different P1 and P2 receptors and are able to release ATP 7, [85] [86] [87] [88] . B cells, for example, release ATP, and extracellular ATP promotes B cell proliferation 87, 88 . In addition to controlling migratory responses in dendritic cells, monocytes, macrophages and eosinophils, extracellular ATP has been shown to regulate the migration of NK cells 89 . Because virtually all mammalian cell types possess purinergic receptors and most, if not all, cells release ATP in response to cell stimulation, there is little doubt that autocrine purinergic mechanisms regulate the functional responses of many of these cell types. Thus, autocrine purinergic signalling seems to be a recurring theme in mammalian cell activation. In support of this conclusion, recent work using human embryonic kidney (heK) cells has revealed that activation of non-immune cells through various adrenergic receptors also requires autocrine signalling through P1 and P2 receptors 90 . Future work in this area will undoubtedly provide exciting new insights into the roles of autocrine purinergic responses in immune cell activation.
ATP as a danger signal
Necrotic and apoptotic cells release ATP, which can serve as a find-me signal that attracts monocytes to phagocytose and remove dead or dying cells 13, 20 . This process involves the activation of P2Y2 receptors on monocytes, which are thought to follow ATP gradients to find their way to apoptotic cells. however, because of the short half-life of ATP in most tissues, it is uncertain whether this process alone could attract phagocytes over long distances 20, 82 . It is more likely that damaged and stressed cells release additional find-me signals that are involved in the recruitment of phagocytes 75, 91 . Recently, formylated peptides, which are released from the mitochondria of damaged cells, have been shown to induce neutrophil activation and chemotaxis in response to severe trauma and sterile inflammation 75, 92 . It is likely that such chemotactic mediators, together with chemokines and ATP, orchestrate the complex processes that guide phagocytes during their long-range approach and final encounter with target cells at inflammatory foci 75 . This may also be true for pathological situations, such as those that follow severe trauma or cancer therapy, in which ATP release and danger signals emitted by damaged cells stimulate host immune responses through Toll-like receptors (TLRs) and NOD-like receptors (NLRs).
Interestingly, recent work has shown that extracellular ATP can promote NLR-mediated inflammasome assembly. Activation of the NOD-, LRR-and pyrin domaincontaining 3 (NLRP3; also known as NALP3) inflammasome has been shown to involve ATP release through pannexin 1 and purinergic signalling through P2X7 receptors. Inflammasome activation triggers innate immune defences by inducing the maturation of pro-inflammatory cytokines, such as IL-1β, in a caspase 1-dependent manner 21, 71, 93 . Activation of the NLRP3 inflammasome has also been observed in response to tumour cell destruction after cancer therapy 20 . This process releases ATP and DAMPs, which stimulate P2X7 receptors and the NLRP3 inflammasome of dendritic cells, facilitating IL-1β production and promoting immunity against tumours 94 . The exact mechanisms that link purinergic signalling to NLRP3 inflammasome activation remain to be determined. however, it is intriguing to speculate that autocrine purinergic signalling events could be involved in this and other immune cell responses to DAMPs and PAMPs.
Inhibition of immune responses
Through the various mechanisms described above, extracellular ATP promotes immune cell activation and pro-inflammatory responses, particularly following the acute release of ATP (for example, in response to cell stimulation, stress or tissue damage) and when extracellular ATP is present at high concentrations. however, ATP can also have anti-inflammatory effects, especially when extracellular ATP is generated chronically and at low concentrations 19, 95, 96 . Such dual effects of ATP have been observed in dendritic cells, monocytes, CD4 + T cells and neutrophils 69, [97] [98] [99] [100] [101] . The overall response elicited by each cell type depends on the particular P2 receptor subtypes that are stimulated on the cell surface. P2 receptor desensitization and internalization in response to chronic or high extracellular ATP concentrations and the activation of suppressive P1 and P2 receptors (such as A2A or P2Y11) are additional mechanisms that may affect the responses of different immune cell types to ATP.
T cell suppression. A2 adenosine receptors have a major role in suppressing immune responses. The complex network of ectonucleotidases that regulates the ligand availability for P1 and P2 receptors in different tissues has a central role in defining the immune responses in these tissues 7, 18 . eNTPD1, which converts ATP to AMP (the precursor of adenosine), and ecto-5ʹ-nucleotidase, which generates adenosine from AMP, are particularly important for the balance between the pro-and antiinflammatory effects of released cellular ATP 28 . This can be observed in eNTPD1-deficient mice, which develop more severe injury-induced inflammation than wildtype mice, apparently owing to reduced ATP hydrolysis, adenosine formation and A2A receptor activation 102 . In addition, ecto-5ʹ-nucleotidase has been shown to have important roles in cancer immunity. Several recent studies have demonstrated that cancer cells express high levels of ecto-5ʹ-nucleotidase and thus promote the generation of adenosine, which impairs the functions of anti tumour CD8 + T cells through A2A receptormediated signalling 104 . Similarly, A2A receptor-driven purinergic signalling events attenuate allograft rejection in animal models by impairing T cell responses [105] [106] . eNTPD1 and ecto-5ʹ-nucleotidase are also expressed on the surface of regulatory T (T Reg ) cells, and this allows these cells to convert extracellular ATP to adenosine and suppress effector cells through A2A receptormediated signalling 107 . T Reg cell expression of eNTPD1 has also recently been shown to impair NK cell activity and promote metastatic growth in a mouse tumour model 108 . Thus, the functions of effector T cells can be suppressed by autocrine or paracrine purinergic signalling loops that involve the hydrolysis of extracellular ATP released from T Reg cells, other immune cells or tumour cells. Although much evidence suggests that A2A receptors have a central role in the downregulation of T cell functions, the extent to which P2Y receptors, and particularly the G s -coupled P2Y11 receptors, can also contribute to this process remains to be seen.
Inhibition of phagocyte function. Neutrophils express the A2A and, to a lesser extent, A2B adenosine receptors, which are G s -coupled P1 receptors. In polarized neutrophils, A2A receptors remain uniformly distributed across the cell surface receptors may provide a global inhibitory signal that is an important requirement for efficient chemotaxis 46 . Neutrophils rapidly convert extracellular ATP to adenosine 12,48 , which can bind to A2A receptors to provide a powerful counterpoint to the stimulatory effects of P2Y2 and A3 receptors. Furthermore, the suppressive actions of A2A receptors provide an important mechanism for limiting key neutrophil functions, including the oxidative burst, degranulation and phagocytosis 12, 48, 51, 109 . Because of their predominant role in downregulating the effector functions of neutrophils and other immune cells, A2A receptors have been extensively investigated as targets for anti-inflammatory therapies to treat patients with asthma, arthritis and other acute and chronic inflammatory diseases 110 . and acute coronary syndrome and are thus among the most widely used pharmaceuticals today 111 . Although the pharmacological actions of these drugs are thought to be platelet specific, it is likely that immune cells expressing P2Y12 receptors are also affected (TABLE 1) . One of the most common side effects of clopidogrel is severe neutropaenia, which may be a reflection of such off-target effects of the drug 112 . Compared to the P2 receptors, a much wider selection of powerful and specific drugs is available for the modulation of adenosine receptors [113] [114] [115] . Many of these drugs are derivatives of caffeine and have been extensively tested and shown to be effective in treating acute and chronic inflammatory diseases in preclinical trials 115 . Currently, several drugs are being tested in clinical trials for their efficacy in chronic obstructive pulmonary disease, rheumatoid arthritis and other inflammatory diseases 115 . In preclinical trials, several pharmacological approaches have been used to increase the availability of extracellular adenosine, including blocking adenosine reuptake (for example, with dipyridamole), blocking adenosine conversion to inosine (with ADA inhibitors, such as pentostatin and erythro-9-(2-hydroxy-3-nonyl) adenine (ehNA)), or increasing the release of adenosine from cells (for example, by low-dose treatment with methotrexate 116, 117 ). These approaches have shown strong anti-inflammatory effects in various experimental models, including ischaemia-reperfusion injury, sepsis and airway inflammation 115, 116 . Several studies have shown that the A3 receptor agonist IB-MeCA (N 6 -(3-iodobenzyl)-5ʹ-(N-methylcarbamoyl)adenosine) can ameliorate arthritis symptoms in mouse Box 1 | Remaining questions and future research directions Future research focusing on the specific roles of the different purinergic signalling components in different cell types is likely to yield exciting information. How do the multiple members of the P1 and P2 receptor families, ectonucleotidases and other components assemble to form autocrine purinergic signalling systems that can shape distinct and appropriate immune responses? Which defects of these complex purinergic signalling systems result in immune disorders and which defects can be compensated for; for example, by substitution of a mutated purinergic receptor with another isoform or splice variant?
Although pannexin 1 appears to be a major player in facilitating ATP release from T cells, neutrophils and monocytes, it is still unclear how other ATP release mechanisms (such as vesicular transport) regulate ATP release and how all the possible release mechanisms control cell responses such as antigen recognition, gradient sensing and chemotaxis.
These questions above and a number of other open issues, such as the spatio-temporal aspect of ATP release and the dynamics of ATP hydrolysis, require new analytical tools to assess ATP release. For example, it will be important to develop new imaging methods that are more sensitive and technically less challenging 15, 121 and combine these techniques with assays that allow us to monitor the release of ATP and other nucleotides in situ. For example, Di Virgilio and co-workers recently developed a technique that enables real-time, whole-body imaging of ATP release in mice 122, 123 . Another important question that would benefit from such advanced ATP imaging techniques is how purinergic signalling facilitates intercellular communication among immune cells; for example, between dendritic cells and T cells during antigen presentation. Are some purinergic signalling systems at the immune synapse designed to specifically coordinate intercellular communication, while others serve to amplify activation, like the purinergic systems in chemical and electrical neuronal synapses?
More sophisticated pharmaceutical tools must also be developed to specifically and selectively block different purinergic signalling events. This requires selective inhibitors of release channels, such as pannexin 1, and more selective drugs to target the different P2 receptors, ectonucleotidases, adenosine deaminases and nucleoside transporters.
The purinergic signalling field is still in its infancy and there is much still to be learned before we fully understand the functions of the individual purinergic signalling components. For instance, the roles of the multiple splice variants of the P2X7 receptor are unclear.
Another interesting future direction for research is the investigation of a potentially more universal role for autocrine purinergic signalling in cell activation. What types of cells and receptor classes require purinergic signalling mechanisms for signal amplification? Is purinergic inside-out signalling linked with calcium outside-in signalling and, if so, what mechanisms are involved? models 118, 119 . IB-MeCA has also been tested with positive results in a Phase II trial in patients with rheumatoid arthritis 120 , suggesting that stimulation of A3 receptors attenuates the inflammatory processes involved in rheumatoid arthritis, possibly by A3 receptor desensitization or internalization.
The complexity of the processes by which autocrine and paracrine purinergic signalling mechanisms can control immune cell functions has been a major hurdle in successfully targeting these mechanisms in inflammatory diseases and immune disorders. The rapidly growing knowledge of the purinergic signalling events that regulate immune responses provides new incentives and insights that should foster the development of new drugs and therapeutic approaches to treat major diseases such as chronic obstructive pulmonary disease, ischaemiareperfusion injury, arthritis, sepsis, inflammatory bowel diseases, allergic diseases and asthma.
Concluding perspectives ATP release and autocrine purinergic signalling feedback regulate numerous cellular immune responses through inside-out signalling, and constitute a powerful amplification mechanism to increase the sensitivity and selectivity of immune cells to activating stimuli. Cells need these autocrine amplification mechanisms to tailor their functional responses to various extracellular cues. These autocrine mechanisms act as checkpoints that either enhance or inhibit immune cell activation depending on which purinergic receptors participate in signalling. This concept allows for multifaceted intercellular signalling through purinergic interactions among neighbouring cells and suggests many exciting future directions for research, such as investigating how groups of immune cells use their individual purinergic signalling systems to shape the collective immune response at sites of infection. It will also be very interesting and important to determine how the nature of the surrounding tissue affects the autocrine purinergic signalling systems of individual cells; for example, in neutrophils migrating though different tissues in order to reach their target destination. A number of questions remain to be answered before we can fully understand the diverse roles of autocrine purinergic signalling in immune cell regulation
; a better appreciation of these issues will be important for developing new immunomodulatory therapies that target purinergic receptors. 
